Previous 10 | Next 10 |
IsoRay, Inc. (ISR) Q4 2019 Results Earnings Conference Call September 24, 2019, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - Co-Principal Financial Officer Conference Call Participants Jason Kolbert - Dawson James Ed Woo - Ascendiant ...
IsoRay (NYSEMKT: ISR ): Q4 GAAP EPS of -$0.02 in-line. More news on: IsoRay, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, Wash., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment option...
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date RICHLAND, Wash., Sept. 18, 2019 (GLOBE NEWSWIRE) -- A recent publication is drawing attention for its positive report on a study of the ...
Noteworthy events during the week of September 15 - 21 for healthcare investors. More news on: CRISPR Therapeutics AG, Pluristem Therapeutics Inc., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...
RICHLAND, Wash., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial ...
RICHLAND, WASHINGTON, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer treatment applic...
RICHLAND, Wash., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc. ’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for c...
IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...
IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
IsoRay Inc. Company Name:
ISR Stock Symbol:
NYSE Market:
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed b...
C omp any’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced N ew ticker symbol to be NYSE American: CATX RICHLAND,...
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful complet...